You are here

  • Home
  • Archive
  • Volume 29, Issue 5
  • Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy

Article metrics

Article menu
Download PDFPDF
Original research
Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2024

AbstractFullPdf
Nov 202024523952
Dec 202018618327
Jan 2021726825
Feb 2021353111
Mar 202127266
Apr 2021333116
May 202119018616
Jun 202140404
Jul 202173735
Aug 2021555529
Sep 2021434320
Oct 2021968647
Nov 202112212037
Dec 202115014620
Jan 202218921622
Feb 202210310010
Mar 202214513911
Apr 2022171168361
May 2022136137469
Jun 2022110109345
Jul 20221011018
Aug 202224023839
Sep 202226726334
Oct 202250749628
Nov 20222972956
Dec 2022828214
Jan 2023383717
Feb 2023626116
Mar 2023575730
Apr 202317945
May 202318501
Jun 20239011
Jul 202312102
Aug 20237114
Sep 20234801
Oct 202311524
Nov 202311110
Dec 202313906
Jan 20242912
Feb 20246611
Mar 202427822
Total530438391754